Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Cash & Equivalents (2020 - 2025)

iSpecimen (ISPC) has 6 years of Cash & Equivalents data on record, last reported at $2.8 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 58.85% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, up 58.85%, while the annual FY2024 figure was $1.9 million, 19.85% down from the prior year.
  • Cash & Equivalents reached $2.8 million in Q3 2025 per ISPC's latest filing, up from $588775.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $27.7 million in Q4 2021 and bottomed at $588775.0 in Q2 2025.
  • Average Cash & Equivalents over 5 years is $8.9 million, with a median of $2.8 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 3886.01% in 2021, then crashed 91.54% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $27.7 million in 2021, then tumbled by 44.81% to $15.3 million in 2022, then tumbled by 84.69% to $2.3 million in 2023, then decreased by 19.85% to $1.9 million in 2024, then surged by 48.14% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.8 million in Q3 2025, $588775.0 in Q2 2025, and $782563.0 in Q1 2025.